Pharma: Clinic Roundup
Friday, June 15, 2012
Teva Pharmaceutical Industries Ltd., of Jerusalem, reported top-line data from the Phase III GALA (Glatiramer Acetate Low-Frequency Administration) trial testing 40 mg/1 ml glatiramer acetate (GA 40 mg/1 ml) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis patients.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.